Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference
ACLX(NASDAQ:ACLX) REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 2025 Morgan Stanley Global Healthcare Conference on Wednesday, September 10, 2025 at 1:05 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in
Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights
ACLXREDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the second quarter ended June 30, 2025. “The data presented for all 117 patients enrolled in the registrational iMMagine-1 study continue to demonstrate anito-cel’s potential to be a life-changing therapy for mu
Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday
ACLXArcellx Announces New Data For Its iMMagine-1 Study In Patients With Relapsed And/Or Refractory Multiple Myeloma; Results From All 117 Patients Dosed In The Pivotal Phase 2 iMMagine-1 Study Of Anito-Cel Demonstrated 97% ORR And 68% CR/sCR At A Median Fol
ACLXScotiabank Maintains Sector Outperform on Arcellx, Lowers Price Target to $93
ACLXArcellx Q1 EPS $(1.13) Misses $(0.77) Estimate, Sales $8.13M Miss $20.06M Estimate
ACLXCognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday
ACLXArcellx FY 2024 GAAP EPS $(2.00) Misses $(1.66) Estimate, Sales $107.936M Miss $121.765M Estimate
ACLXGilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
ACLXGilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.
(ACLX) - Analyzing Arcellx's Short Interest
ACLXLululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
ACLXMorgan Stanley Maintains Overweight on Arcellx, Raises Price Target to $106
ACLXB of A Securities Maintains Buy on Arcellx, Raises Price Target to $100
ACLXBaird Maintains Outperform on Arcellx, Raises Price Target to $106
ACLXNavigating 7 Analyst Ratings For Arcellx
ACLXHC Wainwright & Co. Maintains Buy on Arcellx, Raises Price Target to $95
ACLXNeedham Reiterates Buy on Arcellx, Maintains $96 Price Target
ACLXArcellx To Present Clinical Data for Phase 1 And iMMagine-1 Studies At 66th ASH Annual Meeting; Median Not Reached For Phase 1 Study Of Anito-cel
ACLXNeedham Reiterates Buy on Arcellx, Maintains $96 Price Target
ACLXStocks That Hit 52-Week Lows On Tuesday
ACLXTuesday's session saw 211 companies set new 52-week lows.
